Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Más filtros

Banco de datos
Tipo de estudio
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
PLoS Comput Biol ; 16(8): e1008107, 2020 08.
Artículo en Inglés | MEDLINE | ID: mdl-32810158

RESUMEN

Standard treatment for active tuberculosis (TB) requires drug treatment with at least four drugs over six months. Shorter-duration therapy would mean less need for strict adherence, and reduced risk of bacterial resistance. A system pharmacology model of TB infection, and drug therapy was developed and used to simulate the outcome of different drug therapy scenarios. The model incorporated human immune response, granuloma lesions, multi-drug antimicrobial chemotherapy, and bacterial resistance. A dynamic population pharmacokinetic/pharmacodynamic (PK/PD) simulation model including rifampin, isoniazid, pyrazinamide, and ethambutol was developed and parameters aligned with previous experimental data. Population therapy outcomes for simulations were found to be generally consistent with summary results from previous clinical trials, for a range of drug dose and duration scenarios. An online tool developed from this model is released as open source software. The TB simulation tool could support analysis of new therapy options, novel drug types, and combinations, incorporating factors such as patient adherence behavior.


Asunto(s)
Antituberculosos/uso terapéutico , Modelos Teóricos , Tuberculosis Pulmonar/tratamiento farmacológico , Antituberculosos/administración & dosificación , Antituberculosos/farmacocinética , Quimioterapia Combinada , Humanos , Cumplimiento de la Medicación
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA